Questions raised on very intensive glucose lowering in type 2 diabetes

March 2008    Volume 15, Issue 2   Br J Cardiol 2008;15:68-9

Authors:
BJCardio editorial team

The results of two major trials of intensive glucose lowering in patients with type 2 diabetes appear to have reached different conclusions.

The ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial, conducted by the US National Heart, Lung, and Blood Institute (NHLBI), was stopped in February because the group being treated with intensive glucose lowering was showing a higher mortality rate than the group receiving standard treatment. But just days later, the group organising another similar trial, ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), announced that preliminary results of their study did not confirm the adverse mortality trend with intensive treatment reported from the ACCORD study.

back to top

Comments

There are currently no comments for this article - leave a comment

You must be logged in to post a comment.
Not yet a member? Register now for free.

back to top